<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7423503\results\search\country\results.xml">
  <result pre="heart failure [70]. According to the National Health Commission of" exact="China" post="(NHC), 58% of COVID-19 patients with dire symptoms had"/>
  <result pre="a group of hospitalized patients. This percentage was 5% in" exact="China" post="and 3.7% with Dutch COVID-19 patients [75]. The risk"/>
  <result pre="The virus has been associated with 5 GBS cases in" exact="Italy" post="and 2 GBS cases in Wuhan [75]. In addition"/>
  <result pre="Health Officials imposed new safety measures for the citizens of" exact="Spain" post="[78]. These measures included avoiding public gatherings in closed"/>
  <result pre="in an eerily similar fashion. The virus originated in Wuhan," exact="China" post="with the first case documented in December 2019. After"/>
  <result pre="controlling disease outbreaks. This practice was commonly employed in fourteenth-century" exact="Italy" post="when ships coming from a plague-infected port arrived at"/>
  <result pre="coming from a plague-infected port arrived at a port in" exact="Italy" post="[79]. The ships were required to anchor and wait"/>
  <result pre="returned from a country with high COVID-19 rates such as" exact="China" post="were subjected to a mandatory 2-week quarantine. Some countries"/>
  <result pre="exposed, infectious, and recovered state [80]. Preventive measures taken in" exact="China" post="such as travel bans, home quarantine, and extended vacations"/>
  <result pre="pneumonia. In a study of patients using the drug in" exact="the United States," post="70% of patients had improvement in regards to oxygen"/>
  <result pre="In a study of patients using the drug in the" exact="United States," post="70% of patients had improvement in regards to oxygen"/>
  <result pre="mechanical ventilation [89]. Currently, there are four clinical trials in" exact="the United States," post="and two additional trials in China registered on ClinicalTrials.gov"/>
  <result pre="ventilation [89]. Currently, there are four clinical trials in the" exact="United States," post="and two additional trials in China registered on ClinicalTrials.gov"/>
  <result pre="trials in the United States, and two additional trials in" exact="China" post="registered on ClinicalTrials.gov [88]. Remdesivir serves as a promising"/>
  <result pre="of convalescent plasma for COVID-19. Small clinical studies conducted in" exact="the US" post="and East Asian countries have displayed an increase in"/>
  <result pre="of the immune system [102]. In another clinical study in" exact="South Korea," post="two patients received convalescent plasma treatment. Similar to the"/>
  <result pre="are no approved MSC-based treatments or therapies. Preliminary results from" exact="the US" post="and China demonstrate improved immune function without adverse events"/>
  <result pre="MSC-based treatments or therapies. Preliminary results from the US and" exact="China" post="demonstrate improved immune function without adverse events in COVID-19"/>
  <result pre="lives of the vast majority of the human population. Despite" exact="the US" post="leading the world at 2.1Ã‚ million confirmed cases and"/>
  <result pre="have begun reopening in response to an economic crisis [1]." exact="Georgia" post="was the first state to begin reopening businesses on"/>
  <result pre="the spike proteinProceedings of the National Academy of Sciences of" exact="the United States" post="of America201411142152141521925288733 19.BelouzardSChuVCWhittakerGRActivation of the SARS coronavirus spike protein"/>
  <result pre="spike proteinProceedings of the National Academy of Sciences of the" exact="United States" post="of America201411142152141521925288733 19.BelouzardSChuVCWhittakerGRActivation of the SARS coronavirus spike protein"/>
  <result pre="two distinct sitesProceedings of the National Academy of Sciences of" exact="the United States" post="of America2009106145871587619321428 20.HeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannSTMPRSS2 and ADAM17 cleave ACE2 differentially and"/>
  <result pre="distinct sitesProceedings of the National Academy of Sciences of the" exact="United States" post="of America2009106145871587619321428 20.HeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannSTMPRSS2 and ADAM17 cleave ACE2 differentially and"/>
  <result pre="Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease," exact="United States." post="Emerging Infectious Disease Journal, 26(9). Advance online publication. 39.Guan,"/>
  <result pre="COVID-19 patients. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America, 117(17), 9490-6. 103.ShenCWangZZhaoFm YangYLiJYuanJWangFLiDYangMXingLWeiJXiaoHYangYJiuxinQQingLChenLXuZPengLLioYZhengHChenFHuangKJiangYLiuDZhangZLiuYLiuLTreatment of 5 critically"/>
  <result pre="patients. Proceedings of the National Academy of Sciences of the" exact="United States of America," post="117(17), 9490-6. 103.ShenCWangZZhaoFm YangYLiJYuanJWangFLiDYangMXingLWeiJXiaoHYangYJiuxinQQingLChenLXuZPengLLioYZhengHChenFHuangKJiangYLiuDZhangZLiuYLiuLTreatment of 5 critically ill patients"/>
 </snippets>
</snippetsTree>
